Boston Scientific Acquires Silk Road Medical for $27.50 per Share
June 18, 2024
Boston Scientific Corporation agreed to acquire Silk Road Medical, Inc. for $27.50 per share in an all-cash transaction valuing Silk Road's equity at approximately $1.26 billion. The acquisition brings Silk Road's TransCarotid Artery Revascularization (TCAR) platform into Boston Scientific's vascular portfolio to expand treatment options for carotid artery disease and strengthen the company's vascular technology offerings.
- Buyers
- Boston Scientific Corporation
- Targets
- Silk Road Medical, Inc.
- Sellers
- Silk Road Medical stockholders
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Boston Scientific Acquires BTG plc
August 19, 2019
Medical Devices
Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.
-
Boston Scientific Acquires Axonics, Inc.
November 15, 2024
Medical Devices
Boston Scientific Corporation agreed to and completed the acquisition of Axonics, Inc., a publicly traded medical technology company focused on sacral neuromodulation and urology devices, for $71 per share (approximately $3.7 billion equity value). The deal expands Boston Scientific’s urology portfolio by adding Axonics’ SNM therapy products and related technologies, expected to be accretive to its Urology business over time.
-
Boston Scientific Acquires Baylis Medical Company Inc.
October 6, 2021
Medical Devices
Boston Scientific Corporation agreed to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition expands Boston Scientific’s electrophysiology and structural heart portfolios by adding Baylis’s RF NRG and VersaCross transseptal platforms and complementary guidewires, sheaths and dilators; Baylis was expected to generate nearly $200 million in net sales in 2022.
-
Bristol Myers Squibb Acquires Karuna Therapeutics
December 22, 2023
Biotechnology
Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $330 per share in an all-cash transaction valued at approximately $14.0 billion (about $12.7 billion net of cash). The acquisition adds Karuna's lead neuroscience asset KarXT and its early-stage pipeline to BMS's neuroscience portfolio, accelerating capability and late-stage product expansion in psychiatric and neurodegenerative disorders.
-
Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B
March 3, 2021
Medical Devices
Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.
-
HighBar Partners Acquires SilkRoad Technology
September 16, 2021
Cloud & SaaS
HighBar Partners has acquired SilkRoad Technology and provided additional growth equity financing to accelerate development of SilkRoad’s SaaS talent-management platform. Existing investors Foundation Capital and Two Sigma Ventures are participating in the financing; debt financing for the transaction was provided by Bridge Bank.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.